leadf
logo-loader
viewBiocept Inc
(
NASDAQ:BIOC
)

Biocept to provide coronavirus test kits, will cover out-of-network patients for liquid biopsy tests

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall and CFO Tim Kennedy tell Proactive the California-based firm has solved supply chain problems of obtaining 10,000 testing kits to provide coronavirus test to patients.

Separately, Nall says the firm has agreed to a managed care provider agreement with Medical Cost Containment Professionals LLC (MCCP) to process out-of-network insurance claims for its Target Selector liquid biopsy testing.

Quick facts: Biocept Inc

Follow
NASDAQ:BIOC

Price: 4.01 USD

Market Cap: $59.04 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Biocept approved for expanded Medicare coverage for its Target Selector...

Biocept Inc (NASDAQ:BIOC) (NASDAQ:BIOC) (FRA:B003) CEO Mike Nall tells Proactive it has received a positive final Local Coverage Determination from the Centers for Medicare & Medicaid Services Molecular Diagnostics Program, which will expand Medicare coverage for use of Biocept’s Target...

on 07/27/2021

2 min read